Concepedia

Hidenori Fujita

HF

9

Publications

364

Citations

9

H-Index

1983

Active since

Affiliations

Taiho Pharmaceutical (Japan)(Current)

Cancer Research UK

University of Cambridge

Tokyo University of Agriculture and Technology

Hidenori Fujita is an author at Taiho Pharmaceutical (Japan) specializing in cell biology, medicine, and cancer genetics.

ORCID

Top concepts

Publications per year

1983–2023

9

Publications

9

Futibatinib Is a Novel Irreversible FGFR 1–4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors

Hiroshi Sootome, Hidenori Fujita, Kenjiro Ito et al. · Cancer Research · 2020 · 184 citations · Full text

The Novel VEGF Receptor/MET–Targeted Kinase Inhibitor TAS-115 Has Marked <i>In Vivo</i> Antitumor Properties and a Favorable Tolerability Profile

Hidenori Fujita, Kazutaka Miyadera, Masanori Kato et al. · Molecular Cancer Therapeutics · 2013 · 37 citations

Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations

Isao Miyazaki, Igor Odintsov, Keiji Ishida et al. · Nature Cancer · 2023 · 30 citations · Full text

Abstract A270: TAS-120, a highly potent and selective irreversible FGFR inhibitor, is effective in tumors harboring various FGFR gene abnormalities.

Hiroaki Ochiiwa, Hidenori Fujita, Kimihiro Itoh et al. · Molecular Cancer Therapeutics · 2013 · 28 citations

, , +16

The MET/Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted Tyrosine Kinase Inhibitor Also Attenuates FMS-dependent Osteoclast Differentiation and Bone Destruction Induced by Prostate Cancer

Kenta Watanabe, Michiko Hirata, Tsukasa Tominari et al. · Journal of Biological Chemistry · 2016 · 26 citations · Full text

, , +7

Rows per page

1–5 of 9